eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Original paper

Lymphoid environment in molecular subtypes of breast cancer

Anna Glajcar, Joanna Szpor, Katarzyna Ewa Tyrak, Joanna Streb, Diana Hodorowicz-Zaniewska, Krzysztof Okoń

Pol J Pathol 2018; 69 (2): 169-181
Online publish date: 2018/07/06
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Recently, a large body of evidence has shown that the microenvironment of invasive breast carcinoma affects its development and the patient’s outcome, and vice versa – cancer cells express factors that modulate tumour milieu in terms of its composition and function. We performed an immunohistochemical (IHC) staining of 108 formalin-fixed, paraffin-embedded (FFPE) tissue samples to investigate the relationships between T-cell, B-cell, and NK-cell infiltrate, invasive breast carcinomas molecular subtypes, and other prognostic indicators. The main findings of our study were as follows: the significantly higher infiltrate of the analysed immune cell subsets in triple-negative (TNBC), HER2-positive, non-luminal and luminal B/HER2+ breast carcinomas than in luminal A cancers; their higher densities in poorly differentiated lesions; correlations between lymphoid cells and the expression of hormonal receptors, HER2 receptor status, and marker of cancer proliferation. Furthermore, we observed T-cell numbers to be associated with greater tumour diameter. In summary, the results of our study indicate associations between tumoural lymphoid infiltration and the unfavourable intrinsic subtypes as well as other detrimental prognostic factors in invasive breast carcinomas.

breast cancer, T-lymphocytes, B-lymphocytes, natural killer cells, tumour microenvironment

Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience 2015; 9: 518.
Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 2015; 17: 60.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
Ahn SG, Jeong J, Hong S, et al. Current Issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer.
J Pathol Transl Med 2015; 49: 355-363.
Carvalho MI, Pires I, Prada J, et al. A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int 2014; 2014: 130894.
de la Cruz-Merino L, Barco-Sanchez A, Henao CF, et al. New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013; Article ID: 785317.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014. Ann Oncol 2015; 26: 259-271.
Yamaguchi R, Tanaka M, Yano A, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 2012; 43: 1688-1694.
Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27: 16-25.
Matsumoto H, Koo S, Dent R, et al. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 2015; 68: 506-510.
Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003; 63: 3275-3280.
Ascierto ML, Idowu MO, Zhao Y, et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 2013; 11: 145.
Roberti MP, Mordoh J, Levy EM. Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol 2012; 3: 375.
Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 2006; 59: 972-977.
Mahmoud SMA, Lee AHS, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012; 132: 545-553.
Fu Z, Zuo Y, Li D, et al. The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts. Acta Oncol 2013; 52: 1760-1770.
Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis 2004; 20: 145-153.
Renner K, Singer K, Koehl GE, et al. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol 2017; 8: 248.
Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev 2017; 35: 7-14.
Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003; 52: 715-738.
Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 2016; 4: 59.
Melichar B, Študentova H, Kalábová H, et al. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 2014; 34: 1115-1125.
Mohammed ZM, Going JJ, Edwards J, et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2013; 109: 1676-1684.
Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2013; 2: e24720.
Zhang Z, Zhu Y, Wang Z, et al. Yin-yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy. Cancer Lett 2017; 393: 1-7.
Kmieciak M, Basu D, Payne KK, et al. Activated NK T cells and NK cells render T cells resistant to MDSC and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011; 187: 708-717.
Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer – Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer JClin 2017; 67: 290-303.
Glajcar A, Szpor J, Pacek A, et al. The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment. Virchows Arch 2017; 470: 505-515.
Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 3997-4013.
Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546.
Dong DD, Yie S, Li K, et al. Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol 2012; 73: 998-1004.
Kim JY, Heo S-H, Choi SK, et al. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. Virchows Arch 2017; 470: 381-389.
Tsang JYS, Hui SW, Ni YB, et al. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast Cancer Res Treat 2014; 143: 1-9.
Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007; 9: R15.
Nagalla S, Chou JW, Willingham MC, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013; 14: R34.
Ali HR, Chlon L, Pharoah PDP, et al. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med 2016; 13: e1002194.
Cimino-Matthews A, Ye X, Meeker A, et al. Metastatic Triple Negative Breast Cancers at First Have Fewer Tumor-Infiltrating Lymphocytes Than Their Matched Primary Breast Tumors: A Pilot Study. Hum Pathol 2013; 44: 2055-2063.
Helal TE, Ibrahim E, Alloub AI. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian J Pathol Microbiol 2013; 56: 89-93.
Eiró N, Pidal I, Fernandez-Garcia B, et al. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One 2012; 7: e52796.
Rathore AS, Kumar S, Konwar R, et al. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 2013; 50: 239-244.
Morita M, Yamaguchi R, Tanaka M, et al. Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes. J Clin Pathol 2016; 69: 890-898.
Kim JH, Chon SK, Im KS, et al. Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study. Can J Vet Res 2013; 77: 142-149.
Yajima R, Yajima T, Fujii T, et al. Tumor-infiltrating CD45RO(+) memory cells are associated with a favorable prognosis breast cancer. Breast Cancer 2016; 23: 668-674.
Wakatsuki K, Sho M, Yamato I, et al. Clinical impact of tumor-infiltrating CD45RO+ memory T cells on human gastric cancer. Oncol Rep 2013; 29: 1756-1762.
Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004; 114: 67-76.
Poschke I, De Boniface J, Mao Y, et al. Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. Int J Cancer 2012; 131: 1611-1620.
Vgenopoulou S, Lazaris AC, Markopoulos C, et al. Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. Breast 2003; 12: 172-178.
Ades F, Zardavas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. J Clin Oncol 2014; 32: 2794-2803.
Coronella JA, Spier C, Welch M, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002; 169: 1829-1836.
Pavoni E, Monteriù G, Santapaola D, et al. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol 2007; 7: 70.
Santoiemma PP, Reyes C, Wang LP, et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 2016; 143: 120-127.
Olkhanud PB, Damdinsuren B, Bodogai M, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T regulatory cells. Cancer Res 2011; 71: 3505-3515.
Engels CC, Fontein DB, Kuppen PJ, et al. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. Br J Cancer 2014; 111: 532-538.
Roncati L, Barbolini G, Piacentini F, et al. Prognostic Factors for Breast Cancer: an Immunomorphological Update. Pathol Oncol Res 2015; 22: 449-452.
Gillgrass A, Gill N, Babian A, et al. The absence or overexpression of IL-15 drastically alters breast cancer metastasis via effects on NK cells, CD4 T cells, and macrophages. J Immunol 2014; 193: 6184-6191.
Mamessier E, Bourgin C, Olive D. When breast cancer cells start to fend the educational process of NK cells off. Oncoimmunology 2013; 2: e26688.
Lorenzen J, Lewis CE, McCracken D, et al. Human tumour-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4. Br J Cancer 1991; 64: 457-462.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe